294 related articles for article (PubMed ID: 25774587)
21. Clinical applications of therapeutic apheresis.
Balogun RA; Kaplan A; Ward DM; Okafor C; Burns TM; Torloni AS; Macik BG; Abdel-Rahman EM
J Clin Apher; 2010; 25(5):250-64. PubMed ID: 20806279
[No Abstract] [Full Text] [Related]
22. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy.
Lieker I; Slowinski T; Harms L; Hahn K; Klehmet J
J Clin Apher; 2017 Dec; 32(6):486-493. PubMed ID: 28485075
[TBL] [Abstract][Full Text] [Related]
23. A survey of therapeutic hemapheresis in Norway year 2000.
Taraldsrud E; Kvalheim G; Jørstad S; Stavem K; Aandahl GS
Transfus Apher Sci; 2003 Apr; 28(2):135-41. PubMed ID: 12679117
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic Apheresis in Neurological Disorders].
Nakatsuji Y
Brain Nerve; 2021 May; 73(5):425-430. PubMed ID: 34006672
[TBL] [Abstract][Full Text] [Related]
25. Immunoadsorption therapy for myasthenia gravis.
Shibuya N; Sato T; Osame M; Takegami T; Doi S; Kawanami S
J Neurol Neurosurg Psychiatry; 1994 May; 57(5):578-81. PubMed ID: 8201327
[TBL] [Abstract][Full Text] [Related]
26. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.
Berta E; Confalonieri P; Simoncini O; Bernardi G; Busnach G; Mantegazza R; Cornelio F; Antozzi C
Int J Artif Organs; 1994 Nov; 17(11):603-8. PubMed ID: 7744521
[TBL] [Abstract][Full Text] [Related]
27. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
Szpirt W; Somnier F; Nielsen FC; Rødgaard A
Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
[No Abstract] [Full Text] [Related]
28. [Plasma exchange and immunoadsorption].
Dittrich E; Schmaldienst S; Derfler K
Wien Klin Wochenschr; 2007; 119(5-6 Suppl 1):39-53; quiz 54. PubMed ID: 17939280
[No Abstract] [Full Text] [Related]
29. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.
Takamori M; Ide Y
Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553
[TBL] [Abstract][Full Text] [Related]
30. Apheresis in treatment of acute inflammatory demyelinating disorders.
Mühlhausen J; Kitze B; Huppke P; Müller GA; Koziolek MJ
Atheroscler Suppl; 2015 May; 18():251-6. PubMed ID: 25936333
[TBL] [Abstract][Full Text] [Related]
31. Myasthenia gravis therapy: immunoadsorbent may eliminate need for plasma products.
Sawada K; Malchesky PS; Koo AP; Mitsumoto H
Cleve Clin J Med; 1993; 60(1):60-4. PubMed ID: 8443936
[TBL] [Abstract][Full Text] [Related]
32. Recent advances of therapeutic apheresis in Guillain-Barré syndrome.
Haupt WF
Ther Apher; 2000 Aug; 4(4):271-4. PubMed ID: 10975472
[TBL] [Abstract][Full Text] [Related]
33. Plasma exchange in immune-mediated neuropathies.
Lehmann HC; Hartung HP; Meyer Zu Hörste G; Kieseier BC
Curr Opin Neurol; 2008 Oct; 21(5):547-54. PubMed ID: 18769248
[TBL] [Abstract][Full Text] [Related]
34. [Plasmapheresis in patients with myasthenia gravis].
Konishi T
Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
[TBL] [Abstract][Full Text] [Related]
35. Semi-selective immunoadsorption treatment in myasthenia gravis.
Splendiani G; Passalacqua S; Barbera G; Sturniolo G; Costanzi S; Fulignati P; Casciani CU
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1145-51. PubMed ID: 1457688
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients.
Benny WB; Sutton DM; Oger J; Bril V; McAteer MJ; Rock G
Transfusion; 1999 Jul; 39(7):682-7. PubMed ID: 10413274
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic apheresis in neurological disorders.
Weinstein R
J Clin Apher; 2000; 15(1-2):74-128. PubMed ID: 10767052
[No Abstract] [Full Text] [Related]
38. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
[TBL] [Abstract][Full Text] [Related]
39. Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.
Mathis S; Vallat JM; Magy L
Immunotherapy; 2016 Feb; 8(2):165-78. PubMed ID: 26809024
[TBL] [Abstract][Full Text] [Related]
40. [Plasmapheresis in neurology -- personal experience].
Załeska B; Domzał T; Korsak J
Neurol Neurochir Pol; 1994; 28(2):167-74. PubMed ID: 8047226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
